ProQR Therapeutics (PRQR) Non-Current Deffered Revenue (2021 - 2024)
Historic Non-Current Deffered Revenue for ProQR Therapeutics (PRQR) over the last 4 years, with Q4 2024 value amounting to $31.4 million.
- ProQR Therapeutics' Non-Current Deffered Revenue fell 3382.81% to $31.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $31.4 million, marking a year-over-year decrease of 3382.81%. This contributed to the annual value of $31.9 million for FY2024, which is 3333.51% down from last year.
- Latest data reveals that ProQR Therapeutics reported Non-Current Deffered Revenue of $31.4 million as of Q4 2024, which was down 3382.81% from $47.5 million recorded in Q4 2023.
- ProQR Therapeutics' 5-year Non-Current Deffered Revenue high stood at $66.9 million for Q4 2022, and its period low was $16.8 million during Q4 2021.
- Moreover, its 4-year median value for Non-Current Deffered Revenue was $39.5 million (2024), whereas its average is $40.7 million.
- Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 29815.23% in 2022, then tumbled by 3382.81% in 2024.
- ProQR Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $16.8 million in 2021, then skyrocketed by 298.15% to $66.9 million in 2022, then dropped by 28.96% to $47.5 million in 2023, then crashed by 33.83% to $31.4 million in 2024.
- Its Non-Current Deffered Revenue was $31.4 million in Q4 2024, compared to $47.5 million in Q4 2023 and $66.9 million in Q4 2022.